We are an Osaka University spin-out drug discovery startup, co-developing a novel cancer immunotherapy with Osaka University. Our proprietary platform, HVJ-E/IM-0101, converts neutrophils into the anti-tumor N1 phenotype and, through local administration, remodels the systemic tumor microenvironment (TME) toward an anti-tumor state. This enables activation of neutrophils—the most abundant immune cell type—previously difficult to harness with existing approaches. Building on accumulated clinical safety data of IM-0101 and tumor immune amplification via CXCL2 gene delivery, we plan to expand to IM-0102 for lung cancer over the next few years.
A biotech startup developing T-cell and NK-cell therapies derived from low-immunogenicity iPS cells. It aims to provide new treatments for solid tumors and autoimmune diseases, contributing to the treatment of previously difficult-to-treat intractable diseases.
A startup overcoming challenges in exosome purification with proprietary high-purity, high-yield technology, offering end-to-end support from research to manufacturing. It accelerates practical applications in drug discovery, contributing to a new foundation for pharmaceutical development and driving medical innovation.
Development of technology for assessing micronutrient intake using hair and provision of analysis services.
As a drug discovery venture originating from Kyoto University, we are developing RN-501, a novel boron-containing drug for boron-neutron capture therapy (BNCT), a next-generation cancer radiation therapy targeting intractable cancers. Through proprietary boron carbide nanoparticle technology and polyglycerol modification, RN-501 achieves high tumor selectivity and accumulation, along with potent cancer-killing and immune-activating effects with a single intravenous administration, overcoming the limitations of existing drugs. As Japan's first and the world's first nano-BNCT drug, we aim for early societal implementation.